Advanced renal cell carcinoma (RCC) is responsive to a graft-vs-tumor (GVT) effect following reduced-intensity conditioning (RIC) and allogeneic hematopoietic stem cell transplantation (HCT). 1, 2 However, enthusiasm for the approach has been tempered by the low rate of complete responders and treatment-related toxicities that include graft-vs-host disease and infectious complications. In their recent report, Bregni and co-workers observed a 5-year survival rate of 20% for 25 patients with metastatic RCC treated by RIC and allogeneic HCT from HLA-compatible sibling donors. Of interest, three long-term survivors had stable metastatic disease and had received post transplant vascular endothelial growth factor (VEGF) receptortargeted tyrosine kinase inhibitors including sunitinib or sorafenib. 3 The authors further speculate on the potential for clinical benefit by combining allogeneic HCT with novel targeted therapies for metastatic RCC.
Retrospective analyses of RCC patients treated by RIC and allogeneic HCT have suggested that RCC patients from favorable or intermediate risk groups defined by the Memorial Sloan-Kettering Cancer Center prognostic criteria and with clear-cell tumors have achieved better outcomes. 2, 3 However, RCC patients with these clinical features are most likely to receive initial treatment with VEGF-targeted therapies including sunitinib or bevacizumab plus IFN-a based on the results of phase III clinical studies. 4, 5 The optimal salvage strategy for patients failing VEGF-directed therapies remains unclear. Inhibitors of the mammalian target of rapamycin kinase (mTOR inhibitors) including temsirolimus, everolimus and rapamycin have clinical activity against RCC as monotherapy. For patients with clear-cell RCC receiving second-line everolimus after failing a VEGF-directed therapy, the magnitude of clinical benefit was modest, with an objective response rate of only 1% and a median PFS of 4.0 months. 6 Thus, the potential for combining mTOR inhibitors with other therapies is of significant interest.
Improved survival for lymphoma patients treated by RIC and allogeneic HCT who also received post transplant rapamycin has recently been reported. 7 The OS benefit for the patient cohort treated with rapamycin was due to a significant decrease in post transplant relapse or progression (hazard ratio of 0.5). The authors speculated that the benefit of rapamycin in combination with RIC allogeneic HCT for lymphoma was related to a direct antitumor effect of the mTOR inhibitor. These observations may have important relevance to efforts to treat RCC by allogeneic HCT.
The onset of RCC regression following allogeneic HCT is typically delayed by several months, and early post transplant disease progression has been strongly associated with treatment failure and short survival. [1] [2] [3] Recognizing that good performance patients with clear-cell RCC seeking experimental therapies will likely have failed one or more prior VEGF-targeted treatments, combining allogeneic HCT with an mTOR inhibitor represents a compelling strategy that may delay post transplant tumor progression favoring the development of GVT activity. In vitro, rapamycin can be shown to have a direct cytostatic effect against RCC tumor cell lines at concentrations corresponding to dosing targets used clinically (3-12 ng/ml) 7 ( Figure 1 ). Our group and others 2, 8, 9 have isolated RCC-reactive cytotoxic CD8
þ T-cell clones from the peripheral blood of RCC patients who experienced tumor regression following allogeneic HCT, supporting the hypothesis that the antitumor effect of allogeneic HCT is mediated by donor (Figure 2) or other characterized minor H Ags (data not shown), suggesting that mTOR inhibition is permissive for a sustained GVT activity at the target cell level for RCC tumors. Although the immunosuppressive properties of mTOR inhibitors on human T-cell responses could interfere with the development of post transplant GVT activity, the clinical observations made with lymphoma patients receiving post transplant rapamycin in addition to our in vitro data provide evidence, suggesting that the composite of mTOR inhibition and allogeneic HCT may favor antitumor effects for RCC.
The addition of a post transplant mTOR inhibitor to RIC and allogeneic HCT for RCC could also represent a platform compatible with the therapeutic manipulation of post transplant CTL responses. For example, ex vivo expansion and post transplant adoptive T-cell therapy of donor-derived T-cell lines or clones targeting RCCassociated Ags with restricted expression in normal tissues, such as HA-1 or HERV-E, could theoretically increase the therapeutic index of allogeneic HCT vs the use of post transplant donor lymphocyte infusions to manage persistent or progressive disease. The practical application of such an approach would currently be limited to a small percentage of the total RCC population because of the low phenotype frequency of the HLA-A*11 restricting allele for HERV-E, heterogeneous expression of HERV-E and HA-1 between RCC tumors, and low probability of disparity rates for individual minor H Ags. 2, 8 Therefore, continued clinical development of RIC and allogeneic HCT for RCC would motivate efforts to identify additional RCC-associated T cell Ags.
We have reported a novel in vitro strategy for the expansion and isolation of RCC-reactive CTL clones using responding T cells collected from HLA-identical allogeneic donors in mixed lymphocyte/tumor cell cultures. 10 Three CD3 þ /CD8 þ /TCRab þ clones have been isolated from an HLA-identical sibling donor that recognized Ags expressed by the stimulating RCC tumor, but not by hematopoietic or fibroblast target cells isolated from the same patient, suggesting tumor-restricted Ag expression. Efforts to further exploit such T-cell clones to direct the identification of novel RCC-associated Ags are ongoing in our laboratory.
